AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8636359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread plus meat (approximately 205 kcal)
Number of subjects: 6
Study 1646924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 1646924 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole
Number of subjects: 0
Study 1646924 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 1646924 — intervention group
Group type: COMPARATOR
Intervention: Plasma NE concentration
Number of subjects: 0
Study 6799074 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided transtracheal brushing-washing
Number of subjects: 20
Study 31971678 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix plus add-back therapy (300 mg twice daily with estradiol 1 mg and norethindrone acetate 0.5 mg once daily)
Number of subjects: 790
Study 31971678 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix alone
Number of subjects: 790
Study 31971678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 790
Study 31319769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 311
Study 31319769 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancies about cannabis use
Number of subjects: 311
Study 27568350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional care (INC) with six meetings with a dietitian
Number of subjects: 87
Study 27568350 — intervention group
Group type: COMPARATOR
Intervention: Control group based on European and American guidelines
Number of subjects: 87
Study 27568350 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of nutritional care
Number of subjects: 87
Study 26773325 — intervention group
Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (1.2 mg·kg(‐1) i.v.)
Number of subjects: 64
Study 26773325 — intervention group
Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (doses from 0.3 to 4.8 mg·kg(‐1))
Number of subjects: 64
Study 26773325 — intervention group
Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (≥2.4 mg·kg(‐1))
Number of subjects: 64
Study 26773325 — intervention group
Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (s.c. administration)
Number of subjects: 64
Study 26773325 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 24268678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory iodine fortification of bread and salt
Number of subjects: 2465
Study 21997675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested water (300 ml labeled with D₂O; osmolality <20 mOsm kg(‐1))
Number of subjects: 36
Study 21997675 — intervention group
Group type: EXPERIMENTAL
Intervention: N-CM (non-compartmental model)
Number of subjects: 36
Study 21997675 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-CM (one-compartment model)
Number of subjects: 36
Study 21997675 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-CM (two-compartment model)
Number of subjects: 36
Study 21997675 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-CM
Number of subjects: 36
Study 19294962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented ginseng (FG)
Number of subjects: 16
Study 19294962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17489911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail/web condition (initial mailed survey followed by web survey to nonrespondents)
Number of subjects: 500
Study 17489911 — intervention group
Group type: COMPARATOR
Intervention: Web/mail condition (initial web survey followed by mailed survey to nonrespondents)
Number of subjects: 500
Study 17489911 — intervention group
Group type: EXPERIMENTAL
Intervention: Web/mail condition
Number of subjects: 500
Study 17489911 — intervention group
Group type: COMPARATOR
Intervention: Mail/web condition
Number of subjects: 500
Study 15462687 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5mg, 25mg, or 50mg, combined, N = 10026)
Number of subjects: 17072
Study 15462687 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, nabumetone, or naproxen, combined, N = 7046)
Number of subjects: 17072
Study 15884512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival MMC (0.2 mg/ml for 3 minutes)
Number of subjects: 41
Study 15884512 — intervention group
Group type: COMPARATOR
Intervention: Intrascleral MMC (0.2 mg/ml for 3 minutes)
Number of subjects: 41
Study 9598903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (10 mg/m2 body surface area/wk)
Number of subjects: 0
Study 9598903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9598903 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine, hydroxychloroquine, auranofin, very low dose methotrexate
Number of subjects: 0
Study 9598903 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions requiring 20 to 30% improvement in 3 to 4 core outcome variables
Number of subjects: 0
Study 9598903 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition resembling the Paulus criteria (4 of 6 core set variables improved by > or = 20%)
Number of subjects: 0
Study 9598903 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition (3 of 6 core set variables improved by > or = 30%, not more than one worsening by > 30%)
Number of subjects: 0
Study 8159444 — intervention group
Group type: COMPARATOR
Intervention: Active control: palatal splint worn 24 h/day
Number of subjects: 63
Study 8159444 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment: full occlusal splint worn 24 h/day
Number of subjects: 63
Study 8159444 — intervention group
Group type: COMPARATOR
Intervention: Passive control: full occlusal splint worn only 30 min at each appointment
Number of subjects: 63
Study 3166632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 3166632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3166632 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 30721109 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Internet-based intervention (deprexis)
Number of subjects: 483
Study 30768428 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring program
Number of subjects: 0
Study 26762375 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child mediation intervention
Number of subjects: 111
Study 26762375 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 111
Study 25886281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation exercise presented in print format
Number of subjects: 0
Study 25886281 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging online self-control training exercise
Number of subjects: 0
Study 25886281 — intervention group
Group type: COMPARATOR
Intervention: Easy training exercise with little self-control demand
Number of subjects: 0
Study 25886281 — intervention group
Group type: COMPARATOR
Intervention: Control irrelevant visualization exercise
Number of subjects: 0
Study 23681967 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human ACE2 (rhACE2) 100-1200 μg/kg single dose
Number of subjects: 100
Study 23681967 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human ACE2 (rhACE2) 400 μg/kg repeated dosing for 3 or 6 days
Number of subjects: 100
Study 23681967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21347821 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTi Hand CAC 30
Number of subjects: 44
Study 21347821 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn (control)
Number of subjects: 44
Study 19685109 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with vecuronium (0.02 mg.kg(‐1))
Number of subjects: 100
Study 19685109 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with rocuronium (0.06 mg.kg(‐1))
Number of subjects: 100
Study 19685109 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.2 microg.kg(‐1).min(‐1) (group A)
Number of subjects: 100
Study 19685109 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at 0.7 microg.kg(‐1).min(‐1) (group B)
Number of subjects: 100
Study 17850526 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-tier formulary adoption
Number of subjects: 0
Study 17850526 — intervention group
Group type: COMPARATOR
Intervention: Two-tier formulary (comparison group)
Number of subjects: 0
Study 15271118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplements provided between breakfast and lunch for 21 consecutive days
Number of subjects: 34
Study 15271118 — intervention group
Group type: COMPARATOR
Intervention: Habitual intake for 21 consecutive days
Number of subjects: 34
Study 12817353 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach
Number of subjects: 233
Study 12817353 — intervention group
Group type: COMPARATOR
Intervention: Postal guideline dissemination
Number of subjects: 233
Study 9685273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive behaviour therapy
Number of subjects: 87
Study 9685273 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling and routine care
Number of subjects: 87
Study 9685273 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 87
Study 8085511 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation
Number of subjects: 0
Study 8085511 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based rehabilitation
Number of subjects: 0
Study 8085511 — intervention group
Group type: COMPARATOR
Intervention: Outpatient departments
Number of subjects: 0
Study 2546659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg b.i.d., orally)
Number of subjects: 6
Study 2546659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1002350 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 1002350 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol
Number of subjects: 0
Study 1002350 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0
Study 1002350 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 1002350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31300907 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (L-PD)
Number of subjects: 149
Study 31300907 — intervention group
Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (O-PD)
Number of subjects: 149
Study 28893812 — intervention group
Group type: EXPERIMENTAL
Intervention: Scribes
Number of subjects: 0
Study 28893812 — intervention group
Group type: COMPARATOR
Intervention: No Scribe (Control)
Number of subjects: 0
Study 26276228 — intervention group
Group type: EXPERIMENTAL
Intervention: FFPE-T (formalin-fixed paraffin embedded tumor)
Number of subjects: 114
Study 26276228 — intervention group
Group type: EXPERIMENTAL
Intervention: FFPE-LN (formalin-fixed paraffin embedded lymph node)
Number of subjects: 114
Study 26276228 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 114
Study 26276228 — intervention group
Group type: EXPERIMENTAL
Intervention: FFPE-T
Number of subjects: 114
Study 26276228 — intervention group
Group type: EXPERIMENTAL
Intervention: FFPE-LN
Number of subjects: 114
Study 23659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 IU/kg for three daily doses)
Number of subjects: 67
Study 23659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (40 mg/kg single dose)
Number of subjects: 67
Study 23659666 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive treatment)
Number of subjects: 67
Study 23659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 67
Study 23659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 67
Study 23659666 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study 21157296 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz/tenofovir/emtricitabine (n = 19)
Number of subjects: 487
Study 21157296 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz/zidovudine/lamivudine (n = 31)
Number of subjects: 487
Study 21157296 — intervention group
Group type: EXPERIMENTAL
Intervention: K103N viral load at least 2000 copies/ml
Number of subjects: 487
Study 19411796 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia learning program for DM diet education using standardized patients
Number of subjects: 108
Study 19411796 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular lectures and multimedia learning program
Number of subjects: 108
Study 19411796 — intervention group
Group type: COMPARATOR
Intervention: Regular lectures only
Number of subjects: 108
Study 17715458 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint action with four hands (dyads)
Number of subjects: 20
Study 17715458 — intervention group
Group type: COMPARATOR
Intervention: Joint action with two hands (dyads)
Number of subjects: 20
Study 17715458 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation and relative phase analyses of force-time functions in dyads
Number of subjects: 20
Study 15069730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion adsorption therapy
Number of subjects: 75
Study 15069730 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 75
Study 15069730 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange plus hemoperfusion adsorption therapy
Number of subjects: 75
Study 11834182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Cupressus arizonica
Number of subjects: 20
Study 11834182 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 9492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 119
Study 9492131 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg)
Number of subjects: 119
Study 9492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (ketorolac and ibuprofen)
Number of subjects: 119
Study 11271189 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 0
Study 11271189 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 0
Study 2577273 — intervention group
Group type: COMPARATOR
Intervention: Maintenance drug treatment
Number of subjects: 0
Study 2577273 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug withdrawal
Number of subjects: 0
Study 792740 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsalmide
Number of subjects: 30
Study 792740 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 30
Study 31802596 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagal nerve stimulation (nVNS) using gammaCore for 4 weeks
Number of subjects: 15
Study 31802596 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagal nerve stimulation (nVNS)
Number of subjects: 15
Study 31707181 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gemcitabine and oxaliplatin (mGemOx) - gemcitabine 900 mg/m2, oxaliplatin 80 mg/m2, maximum 6 cycles
Number of subjects: 243
Study 31707181 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + cisplatin (CisGem) - gemcitabine 1000 mg/m2, cisplatin 25 mg/m2, maximum 8 cycles
Number of subjects: 243
Study 31707181 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 243
Study 31707181 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gemcitabine and oxaliplatin (mGemOx)
Number of subjects: 243
Study 31707181 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + cisplatin (CisGem)
Number of subjects: 243
Study 31707181 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 243
Study 31707181 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicities
Number of subjects: 243
Study 28893900 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200‐1800 mg/d)
Number of subjects: 112
Study 28893900 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20‐80 mg/d)
Number of subjects: 112
Study 28893900 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 112
Study 26049688 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 926
Study 26049688 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial LVSI (3-tiered approach)
Number of subjects: 926
Study 26049688 — intervention group
Group type: EXPERIMENTAL
Intervention: Any degree of LVSI
Number of subjects: 926
Study 26049688 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial LVSI
Number of subjects: 926
Study 23764884 — intervention group
Group type: EXPERIMENTAL
Intervention: KinesioTaping
Number of subjects: 25
Study 23764884 — intervention group
Group type: COMPARATOR
Intervention: ShamTaping
Number of subjects: 25
Study 21946743 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 6
Study 21946743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 19689824 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneipp hydrotherapy (daily, with alternate cold and warm thigh affusions)
Number of subjects: 180
Study 19689824 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy (three times a week)
Number of subjects: 180
Study 19689824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physiotherapy and hydrotherapy (joint-specific physiotherapy three times a week and daily alternate cold and warm thigh affusions)
Number of subjects: 180
Study 16965728 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Number of subjects: 1093
Study 16965728 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI-based therapy
Number of subjects: 1093
Study 16965728 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB-based regimen with strict BP control
Number of subjects: 1093
Study 16965728 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 1093
Study 16876495 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWER (lower body resistance plus jump exercise)
Number of subjects: 59
Study 16876495 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPER + LOWER (lower and upper body resistance plus jump exercise)
Number of subjects: 59
Study 16876495 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 59
Study 16876495 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPER + LOWER
Number of subjects: 59
Study 16876495 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWER
Number of subjects: 59
Study 16876495 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study 12607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 12607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha interferon
Number of subjects: 0
Study 12607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 12607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study 10602973 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 240 mgI/ml
Number of subjects: 421
Study 10602973 — intervention group
Group type: COMPARATOR
Intervention: iohexol 240 mgI/ml
Number of subjects: 421
Study 8529760 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.3 IU/Kg BW at 10-11 p.m.)
Number of subjects: 36
Study 8529760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 36
Study 8529760 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (3 x 100 mg daily)
Number of subjects: 36
Study 1952145 — intervention group
Group type: EXPERIMENTAL
Intervention: ocfentanil 1 microgram/kg
Number of subjects: 60
Study 1952145 — intervention group
Group type: EXPERIMENTAL
Intervention: ocfentanil 3 micrograms/kg
Number of subjects: 60
Study 1952145 — intervention group
Group type: EXPERIMENTAL
Intervention: ocfentanil 5 micrograms/kg
Number of subjects: 60
Study 1952145 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 5 micrograms/kg
Number of subjects: 60
Study 7113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (827 kcal; 35% protein, 64% fat, 1% carbohydrate)
Number of subjects: 0
Study 7113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-containing diet (827 kcal; 35% protein, 36% fat, 29% carbohydrate)
Number of subjects: 0
Study 31791824 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 U DaxibotulinumtoxinA (DAXI)
Number of subjects: 609
Study 31791824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 29623579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Number of subjects: 91
Study 29623579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 91
Study 27574886 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 66
Study 27574886 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin combined with insulin (LMWH+insulin)
Number of subjects: 66
Study 26718754 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic urethrotomy
Number of subjects: 0
Study 26718754 — intervention group
Group type: EXPERIMENTAL
Intervention: Open urethroplasty
Number of subjects: 0
Study 26718754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 23564725 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training program
Number of subjects: 27
Study 19406493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and unfractionated heparin (no specific dosage or duration mentioned)
Number of subjects: 9838
Study 18339730 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM
Number of subjects: 92
Study 18339730 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP/CIM
Number of subjects: 92
Study 18339730 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP
Number of subjects: 92
Study 16641396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Number of subjects: 1877
Study 16641396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 1877